24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis
Introduction
Low-dose aspirin reduces by one-fifth the risk of recurrent arterial thrombosis in patients with coronary artery disease (CAD), and international clinical guidelines recommend that low-dose aspirin is administered once daily in these patients [1]. This treatment strategy reflects that aspirin is considered to sustain adequate platelet inhibition through the 24-hour dosing interval. However, emerging evidence questions this assumption. Recent studies point towards a gradual attenuation of aspirin's antiplatelet effect through 24 h causing increased residual platelet aggregation [2], [3], [4], [5] and cyclooxygenase (COX) activity [4], [5], [6]. Furthermore, pharmacodynamic studies suggest that a twice-daily dosing regimen provides more consistent platelet inhibition through 24 h than does the recommended once-daily regimen [7], [8], [9].
Stent thrombosis (ST) is a devastating complication of percutaneous coronary intervention [10], and the complex pathophysiology of in-stent thrombus formation includes procedural and pharmacological factors [11]. Antiplatelet drugs are essential in maintaining stent patency and preventing stent occlusion [11]; however, in patients with a history of definite ST residual platelet aggregation during aspirin treatment is substantial [12], [13]. Patients with previous definite ST also seem to have an accelerated platelet turnover as indicated by higher levels of immature platelets [12]. Immature platelets are large, reticulated and highly reactive, which renders them prone to thrombus formation. Moreover, given aspirin's plasma half-life of only 20 min, newly formed platelets may produce thromboxane due to uninhibited COX-1 activity. Recent studies have associated an accelerated platelet turnover with increased residual platelet aggregation in different cardiovascular settings [12], [14], [15], [16], [17]. Furthermore, differences in platelet production may contribute to variability in residual platelet aggregation levels because thrombopoietin, the primary hormonal regulator of platelet production, directly affects platelet aggregability [18].
We hypothesized that platelet inhibition by low-dose aspirin is reduced during the standard 24-hour dosing interval. Based on previous studies, this may particularly be the case in patients with previous definite ST. Moreover, we explored whether the recovery of platelet aggregation is particularly pronounced in patients with an accelerated platelet turnover.
Section snippets
Methods
The study was conducted in accordance with the Helsinki II Declaration, and the study protocol was approved by the Central Denmark Region Committees on Biomedical Research Ethics (#2011-0231). Written informed consent was obtained from all participants, of which only healthy volunteers were remunerated for their participation.
Results
Baseline characteristics, concomitant drug use and cardiovascular risk factors are shown in Table 1, and procedural characteristics are shown in Table 2. Participants were 64 ± 11 years old and predominantly men (91%). ST and CAD patients were carefully matched with respect to age, sex and diabetes, but there was an excess of previous myocardial infarction in the ST group explained by the intended selection of stable CAD patients with no history of myocardial infarction. In the ST group, 33
Discussion
This study is the largest to investigate the 24-hour effect of aspirin in a study population including patients with previous definite ST. Overall, platelet aggregation, COX-1 activity and platelet activation increased through 24 h, whereas platelet turnover and thrombopoietin levels remained fairly constant suggesting that aspirin treatment does not directly influence these parameters. However, platelet turnover and thrombopoietin levels were significantly elevated in ST patients, perhaps
Conclusions
Platelet inhibition by aspirin declined significantly during the 24-hour dosing interval in patients with previous definite ST, stable CAD patients and healthy individuals. This study suggests that not all patients derive optimal cardiovascular protection from once-daily aspirin. Increased levels of platelet turnover and thrombopoietin were observed in patients with previous definite ST. This may reflect a thrombotic predisposition in these patients.
Funding
This work was supported by Aarhus University, The A.P. Møller Foundation for the Advancement of Medical Science, Gangstedfonden, and Direktør Kurt Bønnelycke & hustru Grethe Bønnelyckes Fond.
Disclosures
ELG has received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim and Pfizer and serves on advisory boards for AstraZeneca, Bayer, and Bristol-Myers Squibb. SDK has received speaker honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Iroko, Pfizer, and The Medicines Company. LOJ has received an unrestricted grant form Terumo and honoraria from AstraZeneca.
Acknowledgments
The authors thank laboratory technicians Vivi Bo Mogensen, Mai Stenulm Therkelsen, and Nasise Wami for invaluable technical assistance.
References (33)
- et al.
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease
Int J Cardiol
(Jul 1 2011) - et al.
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes
J Thromb Haemost
(Jul 2012) - et al.
Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia
Thromb Res
(Jan 2012) - et al.
Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial
J Am Coll Cardiol
(May 15 2012) - et al.
Stent thrombosis
J Am Coll Cardiol
(Oct 19 2010) - et al.
Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets
JACC Cardiovasc Interv
(Aug 2010) - et al.
Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease
J Am Coll Cardiol
(Aug 26 2008) - et al.
Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease
J Thromb Haemost
(Jan 2011) - et al.
Increased platelet turnover in patients with previous definite stent thrombosis
J Thromb Haemost
(Jul 2011) - et al.
Influence of renal function and platelet turnover on the antiplatelet effect of aspirin
Thromb Res
(Apr 2012)
2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial
J Am Coll Cardiol
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
Blood
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
Blood
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”
J Am Coll Cardiol
Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2
J Thromb Haemost
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents
J Am Coll Cardiol
Cited by (33)
Application of omics beyond the central dogma in coronary heart disease research: A bibliometric study and literature review
2022, Computers in Biology and MedicineCitation Excerpt :This ties in with the benefits of antiplatelet drugs for CHD intervention [46]. On a related note, there have also been studies on residual platelet activity for CHD patients under aspirin treatment, via analysis of several single nucleotide polymorphisms and miRNAs [47,48]. Then again, most of these studies on platelets activity focused on upstream biological processes, and few have addressed the downstream omics [49].
Antiplatelet effect of aspirin during 24 h in patients with type 2 diabetes without cardiovascular disease
2018, Thrombosis ResearchCitation Excerpt :Our study differs from these studies by having a homogeneous population of T2DM without CVD and a control group consisting of sex- and age-matched volunteers without diabetes. In accordance with previous studies [15,25–28], our study showed that patients treated with low-dose aspirin have a time-dependent increase in platelet aggregation through the dosing interval. Our study extends these findings to a well-controlled (HbA1c = 53 ± 12 mmol/mol) population of patients with T2DM and no previous history of CVD.
A 45-SNP genetic risk score is increased in early-onset coronary artery disease but independent of familial disease clustering
2017, AtherosclerosisCitation Excerpt :The present study was a cross-sectional study in patients with early- and late-onset CAD. The recruitment of patients has previously been described in detail [22–24]. Briefly, all patients were recruited from the Western Denmark Heart Registry (WDHR) and interviewed between 2007 and 2015.
A brief review on high on-aspirin residual platelet reactivity
2015, Vascular PharmacologyCitation Excerpt :An increased fraction of newly formed platelets might therefore be a potential mechanism for high-on-aspirin RPR [43]. High-on-aspirin RPR is five-fold more frequent 24 h as compared to 2 h after aspirin ingestion, and this observation has been related to inflammation, current smoking and diabetes [46,47]. The drug–drug interaction between aspirin and ibuprofen is well known to contribute to high-on-aspirin RPR [48,49].
- 1
This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.